Kasturba Medical College, India Wins XV Fujio Cup Quiz in NCRM NICHE 2020
19.10.2020 10:55:00 EEST | Business Wire | Press release
Sufyan Ibrahim and Himanshu Yashavanthi Nagesh of Kasturba Medical College, India, won the prestigious Fujio Cup Quiz (FCQ), an active knowledge gaining academic event of NCRM NICHE 2020, on stem cells and regenerative medicine, in a toughly fought contest among teams representing Monash University, Australia, Birla Institute of Technology (BITS-Pilani), India and Bandung Institute of Technology, Indonesia, who came second. The virtual event had lectures by Prof. Masaharu Seno, Okayama University on induced pluripotent stem cells, Dr Maria Nostro, University of Toronto on pancreatic progenitors for diabetes and Fr Francis Xavier, Loyola College, Chennai in the inter-disciplinary conclave on stress management during Covid-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005298/en/
Winners of XV Fujio Cup Quiz, Dr. Ibrahim and Mr. Nagesh of Kasturba Medical College, India, with the 2020- Joyce and James Till Travel Grant Awardee, Dr. Natarajan, a 2013- FCQ Elite. (Graphic: Business Wire)
Regenerative Medicine is a specialty demanding inter-disciplinary interaction, as physical forces like gravity and elasticity, chemically synthesized polymers and nanomaterial scaffolds, provide suitable micro environment to the cells for in vitro culture in the lab, which are transplanted to replace, restore, repair and regenerate tissues to address organ failures. FCQ, a part of NCRM NICHE started in 2006 is conducted in Tokyo, Japan, since 2017 in which young scholars of different specialties of science from all over the world participate, cross several steps of quizzing and assignments to win the trophy. Alumni of top scoring teams of FCQ (FCQ elites) are eligible to nominate candidates to Edogawa NICHE Prize (www.edogawanicheprize.org). The Joyce and James Till Travel Grant (www.j2t2grant.org) instituted in 2018, with a grant by Prof. James Till, 2018 Edogawa NICHE Prize recipient, was awarded this year to Dr. Rupesh Kumar Natarajan, (2013 FCQ elite), now pursuing fellowship in pediatric cardiology, University of Minnesota, USA.
FCQ as an innovation platform, has started attracting multinational companies for collaboration following development of novel solutions like BEES-HAUS for urethral stricture (https://onlinelibrary.wiley.com/doi/full/10.1111/iju.13852), cartilage repair (https://www.sciencedirect.com/science/article/pii/S2352320420300274) and the recently granted patent on microgravity based enhancement of nitric oxide synthesis by blood cells, specially NK cells.
Dr. Shojiro Katoh, (Founder, EELS) congratulated the winners and hopes to invite to Japan beside honoring the 2020 Edogawa NICHE Prize recipient Dr. John Venter in the coming years, by when the Boron Neutron Capture Therapy (BNCT) in Edogawa Hospital (http://bnct-cancer.com/center.php) could be ready to offer treatment to cancer patients from abroad and start research collaboration with overseas institutes. Event information will be updated in: www.ncrmniche.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005298/en/
Contact information
Samuel JK Abraham
info@gncorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 08:00:00 EEST | Press release
Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of Synocrom™ also builds on Croma-Pharma’s long-standing expertise in the development and manufacturi
Murata Begins Mass Production of Seven Automotive MLCCs with World-leading Capacitance for Their Rated Voltage and Size, Supporting Stable Operation of In-vehicle Systems and Greater Design Flexibility8.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of seven AEC-Q200-qualified multilayer ceramic capacitors (MLCCs) that achieve the world’s largest capacitance for a given rated voltage and size*, supporting stable operation of in-vehicle systems and greater design flexibility. Five parts in the GCM series are rated at 2.5-4 Vdc, targeting IC peripheral circuits in advanced driver assistance systems (ADAS) and autonomous driving (AD) applications. The remaining two MLCCs are rated at 25 Vdc for in-vehicle power line applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407486750/en/ [Murata Manufacturing Co., Ltd.] Seven automotive MLCCs In recent years, as ADAS and AD technologies advance, the number and performance level of systems installed in vehicles have continued to increase. As a result, demand for higher capacitance low-voltage MLCCs used around ICs has grown to e
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7.4.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The equity awards were granted on April 1, 2026 and consisted of options to purchase an aggregate of 117,445 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 55,875 shares. The options have an exercise price per share equal to $5.62, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted s
SLB OneSubsea and Subsea7 Sign Collaboration Agreement with PETRONAS Suriname7.4.2026 23:05:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced the signing of a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331210557/en/ SLB OneSubsea has signed a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea solutions. The agreement establishes a long-term framework for collaboration across the project lifecycle. This approach enables
Nadia Karkar Joins 500 Global as Managing Partner7.4.2026 20:43:00 EEST | Press release
500 Global today announced the appointment of Nadia Karkar as Managing Partner as the firm expands its global investment platform. Nadia’s appointment follows the recent announcement of the appointment of Atul Mehta — former Chief Investment Officer of the International Finance Corporation — to 500 Global's Board of Directors, and reflects the firm's continued build-out of the leadership and capabilities required to deliver on its next stage of global growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407719214/en/ Nadia Karkar Joins 500 Global as Managing Partner Nadia joins from TPG Rise, the $31 billion impact investing platform of TPG Inc., where she most recently served as Head of Business Development, responsible for product innovation, strategic partnerships and corporate development. She played a central role in building TPG Rise Climate’s Global South Initiative, a blended finance vehicle designed to catalyze
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom